1193487-32-9

Upstream product

• 1193488-44-6 5-oxo-7-trifluoromethanesulfonyloxy-1,2,3,5-tetrahydro-indolizine-8-carboxylic acid ethyl ester 
• 72130-68-8 ethyl 7-hydroxy-5-oxo-1,2,3,5-tetrahydro-8-indolizinecarboxylate 
• 1193487-30-7 7-(4-bromo-2-fluoro-phenylamino)-5-oxo-1,2,3,5-tetrahydro-indolizine-8-carboxylic acid ethyl ester 
• 1193487-31-8 7-(4-bromo-2-fluoro-phenylamino)-5-oxo-1,2,3,5-tetrahydro-indolizine-8-carboxylic acid 
• 75647-90-4 O-cyclopropylmethyl-hydroxylamine 

Relevant academic research and scientific papers

MEK INHIBITOR SALTS AND SOLVATES THEREOF

The present invention relates to sodium salt forms of 7-(4-Bromo-2-fluoro- phenylamino)-6-methyl-5-oxo-1,3,5-tetrahydro-indolizine-8-carboxylic acid (2- hydroxyethoxy)-amide and 7-(4-Bromo-2-fluoro-phenylamino)-5-oxo- 1,2,3,5-tetrahydro- indolizine-8-carboxylic acid cyclopropylmethoxy-amide and their corresponding solvates and polymorphs, which are useful in the treatment of a disease, disorder or syndrome associated with MEK inhibition, such as cancer, in mammals.

Heterocyclic Compounds as MEK Inhibitors

The present invention relates to compounds of formula I and pharmaceutically acceptable salts. These compounds can act as potential MEK inhibitors in the treatment of hyperproliferative diseases, like cancer and inflammation. The present invention also reveals methods of preparation thereof.